1. Home
  2. VTAK vs CNSP Comparison

VTAK vs CNSP Comparison

Compare VTAK & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTAK
  • CNSP
  • Stock Information
  • Founded
  • VTAK 2002
  • CNSP 2017
  • Country
  • VTAK United States
  • CNSP United States
  • Employees
  • VTAK N/A
  • CNSP N/A
  • Industry
  • VTAK Medical/Dental Instruments
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • VTAK Health Care
  • CNSP Health Care
  • Exchange
  • VTAK Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • VTAK 4.1M
  • CNSP 4.0M
  • IPO Year
  • VTAK 2018
  • CNSP 2019
  • Fundamental
  • Price
  • VTAK $2.72
  • CNSP $8.95
  • Analyst Decision
  • VTAK
  • CNSP Strong Buy
  • Analyst Count
  • VTAK 0
  • CNSP 1
  • Target Price
  • VTAK N/A
  • CNSP $20.00
  • AVG Volume (30 Days)
  • VTAK 417.2K
  • CNSP 24.1K
  • Earning Date
  • VTAK 11-12-2025
  • CNSP 11-14-2025
  • Dividend Yield
  • VTAK N/A
  • CNSP N/A
  • EPS Growth
  • VTAK N/A
  • CNSP N/A
  • EPS
  • VTAK N/A
  • CNSP N/A
  • Revenue
  • VTAK $600,000.00
  • CNSP N/A
  • Revenue This Year
  • VTAK $822.86
  • CNSP N/A
  • Revenue Next Year
  • VTAK $168.42
  • CNSP N/A
  • P/E Ratio
  • VTAK N/A
  • CNSP N/A
  • Revenue Growth
  • VTAK 37.62
  • CNSP N/A
  • 52 Week Low
  • VTAK $2.20
  • CNSP $4.93
  • 52 Week High
  • VTAK $20.14
  • CNSP $221.94
  • Technical
  • Relative Strength Index (RSI)
  • VTAK 55.54
  • CNSP 51.95
  • Support Level
  • VTAK $2.52
  • CNSP $8.60
  • Resistance Level
  • VTAK $2.83
  • CNSP $9.30
  • Average True Range (ATR)
  • VTAK 0.22
  • CNSP 0.63
  • MACD
  • VTAK -0.01
  • CNSP -0.17
  • Stochastic Oscillator
  • VTAK 28.99
  • CNSP 21.50

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: